LEGN - Legend Biotech Corp

QQQ $ 454.82 $ -3.24 (-0.7 %)

DIA $ 398.57 $ -4.02 (-1.03 %)

SPY $ 530.36 $ -3.71 (-0.7 %)

TLT $ 91.26 $ -1.09 (-1.21 %)

GLD $ 225.37 $ -2.03 (-0.93 %)

Previous Close

$ 42.08

Open

$ 41.11

Bid

$ 0.00 x 0

Ask

$ 42.25 x 200

Day's Range

$ 41.11 - $ 42.28

52 Week Range

$ 39.13 - $ 77.32

Volume

848,492

Average Volume

Market Cap

15.31B

Beta (5Y Monthly)

$ 0.60

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Maintains Buy on Legen...
05/24/2024 10:13:51

HC Wainwright & Co. analyst Mitchell Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and lowers the price targe...

Deutsche Bank Initiates Coverage On Legend...
05/23/2024 17:01:13

Deutsche Bank analyst James Shin initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Buy rating and announces Price Ta...

MaxCyte Signs License Agreement With Legen...
05/22/2024 12:08:34

RBC Capital Maintains Outperform on Legend...
05/14/2024 15:31:54

RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and raises the price target fro...

Legend Biotech Stock: A Deep Dive Into Ana...
05/14/2024 12:00:19

HC Wainwright & Co. Maintains Buy on Legen...
05/14/2024 10:56:55

HC Wainwright & Co. analyst Mitchell Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and lowers the price targe...

Legend Biotech Expects Cash And Equivalent...
05/13/2024 11:04:50

Legend Biotech Q1 2024 GAAP EPS $(0.16) Be...
05/13/2024 11:02:15

Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.34...

HC Wainwright & Co. Reiterates Buy on Lege...
05/09/2024 18:56:45

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...

HC Wainwright & Co. Reiterates Buy on Lege...
04/23/2024 10:19:23

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...

$legend-biotech-announces-carvykti-approved-by-the-european-commission-for-second-line-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma$

Legend Biotech Announces Carvykti Approved...
04/22/2024 17:09:33

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapseLegend Bi...

fda-mandates-boxed-warning-for-bristol-myers-johnson--johnson-car-t-based-blood-cancer-therapies

FDA Mandates "Boxed Warning" For Bristol M...
04/19/2024 13:28:52

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—t...

Analyst Ratings For Legend Biotech
04/17/2024 14:01:36

Scotiabank Upgrades Legend Biotech to Sect...
04/17/2024 12:20:16

Scotiabank analyst George Farmer upgrades Legend Biotech (NASDAQ:LEGN) from Sector Perform to Sector Outperform and maintain...

HC Wainwright & Co. Reiterates Buy on Lege...
04/16/2024 17:10:10

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...

Legend Biotech Earlier Announced CARVYKTI ...
04/16/2024 15:42:49

johnson--johnsons-carvykti-stands-ahead-of-bristol-myers-rival-blood-cancer-therapy-with-fda-approval-for-wider-population

Johnson & Johnson's Carvykti Stands Ahead ...
04/08/2024 18:19:35

FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients...

On Friday April 5, 2024, Legend Biotech Re...
04/08/2024 07:42:07

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapseLegend Bi...

Cantor Fitzgerald Initiates Coverage On Le...
04/03/2024 11:47:47

Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Overweight rating and an...

Unveiling 9 Analyst Insights On Legend Bio...
04/01/2024 12:01:27